Therefore, given the limitations of [18F]FDG in accurately reflecting neuronal integrity in active MS lesions due to the contribution of inflammatory cell metabolism, alternative neurodegeneration markers, such as tau PET imaging, hold potential for evaluating neuronal integrity in MS lesions, though their applicability in MS has yet to be established. The gene discussed is MAPT; the disease is myeloid sarcoma.